Nordea Investment Management AB Grows Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Nordea Investment Management AB grew its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 23.6% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 42,667 shares of the biopharmaceutical company’s stock after buying an additional 8,135 shares during the quarter. Nordea Investment Management AB’s holdings in Regeneron Pharmaceuticals were worth $30,160,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in REGN. International Assets Investment Management LLC lifted its stake in Regeneron Pharmaceuticals by 86,013.3% during the third quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock worth $926,078,000 after purchasing an additional 879,916 shares during the last quarter. Worldquant Millennium Advisors LLC purchased a new position in shares of Regeneron Pharmaceuticals during the third quarter worth approximately $127,489,000. Icon Wealth Advisors LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 18,342.0% in the 3rd quarter. Icon Wealth Advisors LLC now owns 75,981 shares of the biopharmaceutical company’s stock worth $79,874,000 after acquiring an additional 75,569 shares during the last quarter. State Street Corp boosted its stake in shares of Regeneron Pharmaceuticals by 1.3% in the 3rd quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company’s stock valued at $5,153,603,000 after purchasing an additional 61,277 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA grew its holdings in shares of Regeneron Pharmaceuticals by 12.4% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 540,293 shares of the biopharmaceutical company’s stock valued at $567,864,000 after purchasing an additional 59,769 shares during the last quarter. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN opened at $730.30 on Wednesday. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The stock has a market cap of $80.25 billion, a P/E ratio of 18.07, a P/E/G ratio of 2.19 and a beta of 0.10. The business’s 50 day moving average price is $760.25 and its 200-day moving average price is $968.39. Regeneron Pharmaceuticals, Inc. has a 52 week low of $693.00 and a 52 week high of $1,211.20.

Analysts Set New Price Targets

Several analysts have issued reports on REGN shares. Leerink Partnrs lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. StockNews.com cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 4th. Wells Fargo & Company cut their target price on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating on the stock in a report on Tuesday, October 22nd. BMO Capital Markets lowered their price target on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating for the company in a report on Friday, November 1st. Finally, Evercore ISI cut their price target on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating on the stock in a report on Thursday, October 24th. One analyst has rated the stock with a sell rating, six have given a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $1,050.29.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.